Mankind Pharma Ltd., established in 1991 and converted to a public limited company in 2005, is a prominent Indian pharmaceutical company involved in developing, manufacturing, and marketing a wide range of pharmaceutical formulations and consumer healthcare products. The company operates across several therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, respiratory, and more. Mankind Pharma also has a significant presence in the consumer healthcare segment with notable brands like Manforce in condoms and Preganews in pregnancy detection.
With 23 manufacturing facilities across India, Mankind Pharma boasts a substantial production capacity of 40.77 billion units for various dosage forms. The company has expanded its portfolio into chronic and specialty therapeutic segments, animal healthcare, and recently into oncology and transplant segments. Mankind Pharma has a global presence with subsidiaries in the US, Singapore, Nepal, and Dubai. The company plans to raise capital through an Offer for Sale of 40,058,844 equity shares, indicating ongoing growth and expansion strategies.
